A new study by Indiana University School of Medicine researchers has revealed a breakthrough in the fight against acute myeloid leukemia, one of the most aggressive and fatal blood cancers in adults.

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, ...

Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...

Mild CMV reactivation was associated with beneficial effects, while severe cases required treatment, which increased the risk of toxicity and infections.